Table 1.
Clinical characteristics of the study population at admission
| Parameter | ACLF (n = 56) | CHB (n = 30) | Control (n = 30) |
| Male/female | 40/16 | 21/9 | 14/6 |
| Age (yr) | 44 ± 11 | 40 ± 10 | 39 ± 8 |
| Alanine aminotransferase (IU/L) | 145 ± 189 | 71 ± 61 | 21 (10-31) |
| Total bilirubin (mg/dL) | 20.2 ± 5.6 | 2.2 ± 1.3 | 0.7 ± 0.2 |
| Albumin (g/L) | 30.4 ± 4.8 | 33.5 ± 5.2 | 35.6 ± 4.9 |
| BUN (mmol/L) | 4.4 ± 2.1 | 4.1 ± 1.8 | 4.8 ± 1.5 |
| Plasma sodium (mEq/L) | 134.8 ± 4.5 | 135.6 ± 5.7 | 137.4 ± 3.8 |
| Cr (mg/dL) | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 |
| CysC (mg/L) | 1.1 ± 0.4 | 0.7 ± 0.2 | 0.6 ± 0.3 |
| International normalized ratio | 1.9 ± 0.4 | 1.1 ± 0.2 | 0.9 ± 0.1 |
| HBV DNA log10 (IU/mL) | 4.75 ± 2.11 | 6.21 ± 2.78 | |
| Ishak score | ND | 4 (3-5)1 | |
| MELD score | 24 ± 3 | 8 ± 4 |
1
Histopathological data from 20 chronic hepatitis B (CHB) patients. ND: Not determined; BUN: Blood urea nitrogen; Cr: Creatinine; CysC: Serum cystatin C; HBV: Hepatitis B virus; MELD: Model for end-stage liver disease.